20 January 2023 : Clinical Research
Monitoring of Autoantibodies Following Autologous Hematopoietic Stem Cell Transplantation in 6 Children with Recently Diagnosed Type 1 Diabetes Mellitus
Alejandro D. Mesples1ABCDEFG*, Desiree C.T. Cox23ACDEF, Harriet D. Lundy1ADE, Sheena Antonio-Collie1CDG, Charles W. Diggiss1A, Jonathan R.T. Lakey45ACDEFDOI: 10.12659/MSM.938979
Med Sci Monit 2023; 29:e938979
Table 1 Variables analyzed at baseline of patients with autoimmune diabetes who received an autologous bone marrow stem cell transplant.
| Patient age (years) | Ins dose (units) | A1c (%) | Creatinine (mg/dl) | Glyc. control (mg/dl) | C peptide (ng/mL) | ICA (JDF units) | GAD (units/ml) | IA2 (units/ml) | INS AB (units/ml) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Patient 1 | 8 | 30 | 9 | 0.6 | >250 | <0.1 | 17 | 180 | 150 | 1 |
| Patient 2 | 7 | 30 | 10 | 0.9 | <150 | 0.9 | 13 | 250 | 100 | 0.5 |
| Patient 3 | 9 | 40 | 10 | 0.9 | 150–250 | 0.8 | 10 | 200 | 100 | 0.7 |
| Patient 4 | 10 | 45 | 10 | 1.2 | 150–250 | <0.1 | 25 | 350 | 68 | 1 |
| Patient 5 | 6 | 20 | 8 | 0.6 | 150–250 | <0.1 | 15 | 100 | 120 | 0.8 |
| Patient 6 | 7 | 30 | 11 | 0.9 | 150–250 | <0.1 | 12 | 170 | 100 | 0.5 |
| ABMHSC – autologous bone marrow hematopoietic stem cells; Ins Dose – insulin daily dose; A1C – glycosylated hemoglobin A1c; Glyc. Control – glycemic control; ICA – islet cell antibodies; IA2– antibodies against islet antigen-related tyrosine phosphatase 2; GAD – glutamic acid-decarboxylase; AIA – antibodies, anti-insulin antibodies. | ||||||||||